AMGEN and Boehringer Ingelheim said Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell engager that targets B-cell maturation antigen, a potential target for multiple myeloma. BI 836908 (AMG 420) is currently in phase I studies. Under the agreement, Amgen will work with Boehringer...
Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019).
